Hereditary Amyloid Neuropathy

Peripheral Neuropathy

Volumn 2, Issue , 2005, Pages 1921-1935

  Reilly, Mary M ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 14244260857     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-9491-7.50086-7     Document Type: Chapter

References (106)

1. Adams D. Hereditary and acquired amyloid neuropathies. J. Neurol. 2001, 248:647.
2. Adams D., Samuel D., Goulon-Goeau C., et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000, 123:1495.
3. Altland K., Becker P., Banzhoff A. Paraffin oil protected high resolution hybrid isoelectric focusing for the demonstration of substitutions of neutral amino acids in denatured proteins: the case of four human transthyretin (prealbumin) variants associated with familial amyloidotic polyneuropathy. Electrophoresis 1987, 8:293.
4. Alves I.L., Hays M.T., Saraiva M.J.M. Comparative stability and clearance of [Met30] transthyretin and [met119] transthyretin. Eur. J. Biochem. 1997, 249:662.
5. Alves I.L., Jacobson D.R., Torres M.F., et al. Transthyretin Ser 6 as a natural polymorphism in familial amyloidotic polyneuropathy. Amyloid 1996, 3:242.
6. Andersson K., Olofsson A., Nielsen E.H., et al. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem. Biophys. Res. Commun. 2002, 294:309.
7. Andersson R. Hereditary amyloidosis with polyneuropathy. Acta Med. Scand. 1970, 188:85.
8. Ando Y., Ando E., Tanaka Y., et al. De novo amyloid synthesis in ocular tissue in familial amyloidotic polyneuropathy after liver transplantation. Transplantation 1996, 62:1037.
9. Ando Y., Ohlsson P.-I., Suhr O., et al. A new simple and rapid screening method for variant transthyretin (TTR) related amyloidosis. Biochem. Biophys. Res. Commun. 1996, 228:480.
10. Andrade C. A peculiar form of peripheral neuropathy: familial atypical generalized amyloidosis with special involvement of the peripheral nervous system. Brain 1952, 75:408.
11. Araki S., Mawatari S., Ohta M., et al. Polyneuritic amyloidosis in a Japanese family. Arch. Neurol. 1968, 18:593.
12. Araki S., Shigehira Y. Pathology of familial amyloidotic polyneuropathy with TTR Met 30 in Kumamoto, Japan. Neuropathology 2000, 20:S47.
13. Benson M.D. Familial amyloid polyneuropathy. Trends Neurosci. 1989, 12:88.
14. Benson M.D. Inherited amyloidosis. J. Med. Genet. 1991, 28:73.
15. Bergethon P., Sabin T., Dewis D., et al. Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology 1996, 47:944.
16. Bittencourt P.L., Couto C.A., Leitao R.M., et al. No evidence of de novo amyloidosis in recipients of domino liver transplantation: 12 to 40 months (mean 24 month) follow-up. Amyloid 2002, 9:194.
17. Brett M., Persey M.R., Reilly M.M., et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain 1999, 122:183.
18. 2+ stabilization. EMBO J. 2001, 20:6277.
19. Coehlo T. Familial amyloid polyneuropathy: new developments in genetics and treatment. Curr. Opin. Neurol. 1996, 9:355.
20. Cohen A.S. History of amyloidosis. J. Intern. Med. 1992, 232:509.
21. Cohen A.S., Calkins E. Electron microscopic observations on a fibrous component of amyloid of diverse origins. Nature 1959, 183:1202.
22. Costa P., Figueira A.S., Bravo R.R. Amyloid fibril protein related to pre-albumin in familial amyloidotic polyneuropathy. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:4499.
23. Cotton R.G.H. Detection of single base changes in nucleic acids. Biochem. J. 1989, 263:1.
24. Coutinho P., Silva A., Lima J., de Barbosa A. Forty years of experience with type 1 amyloid neuropathy: review of 483 cases. Amyloid and Amyloidosis 1980, 88. Excerpta Medica, Amsterdam. G.G. Glenner, P. Pinho, E. Costa, A. De Freitas (Eds.).
25. de le Chapelle A., Tolvanan R., Boysen G., et al. Gelsolin derived familial amyloidosis caused by asparagine or tyro-sine substitution for aspartic acid at residue 187. Nature 1992, 2:157.
26. de Navasquez S., Treble H.A. A case of primary generalized amyloid disease with involvement of the nerves. Brain 1938, 61:116.
27. Dwulet F.E., Benson M.D. Polymorphism of human plasma thyroxine binding prealbumin. Biochem. Biophys. Res. Commun. 1983, 114:657.
28. Dwulet F.E., Benson M.D. Characterization of a transthyretin (pre-albumin) variant associated with familial amyloidotic polyneuropathy, type II (Indiana/Swiss). J. Clin. Invest. 1986, 78:880.
29. Dyck P.J., Lambert E.H. Dissociated sensation in amyloidosis. Arch. Neurol. 1969, 20:490.
30. Fonseca C., Ceia F., Nogueira J.S., et al. Myocardiopathy caused by Portuguese-type familial amyloidotic polyneuropathy: sequential morphological and functional study of 60 cases. Rev. Port. Cardiol. 1991, 10:909.
31. Ghiso J., Haltia M., Prelli F., et al. Gelsolin variant (ASN 187) in familial amyloidosis, Finnish type. Biochem. J. 1990, 272:827.
32. Gillmore J.D., Stangou A.J., Tennent G.A., et al. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein A1 Gly26Arg. Transplantation 2001, 71:986.
33. Goldsteins S.G., Persson H., Andersson K., et al. Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3108.
34. Goren H., Steinberg M.C., Farboody G.H. Familial oculoleptomeningeal amyloidosis. Brain 1980, 103:473.
35. Gorevic P.D., Munoz P.C., Gorgone G., et al. Amyloidosis due to mutation of the gelsolin gene in an American family with lattice corneal dystrophy type II. N. Engl. J. Med. 1991, 325:1780.
36. Harding A.E., Reilly M.M. Molecular genetics of inherited neuropathies. Peripheral Nerve Disorders 2 1995, 118. Butterworth-Heinemann, Oxford. A.K. Asbury, P.K. Thomas (Eds.).
37. Herlinus G., Larsson M., Erizon B.G. FAP World Transplant Register and Domino/Sequential Register Update: Yearly Report 2001, FAP World Transplant Register, Stockholm.
38. Holmgren G., Ando Y., Wikström L. Discordant symptoms in monozygotic twins with familial amyloidotic polyneuropathy (FAP TTR met30) amyloid. Int. J. Exp. Clin. Invest. 1997, 4:178.
39. Holmgren G., Erizon B.-G., Groth C.-G., et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993, 341:1113.
40. Holmgren G., Steen L., Ekstedt J., et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin. Genet. 1991, 40:242.
41. Hund E., Linke R.P., Willig F., Grau A. Transthyretin-associated neuropathic amyloidosis. Neurology 2001, 56:431.
42. Hungo M., Ikeda S. Echocardiographic assessment of the evolution of amyloid heart disease: a study with familial amyloid polyneuropathy. Circulation 1986, 73:249.
43. Ii S., Sommer S.S. The high frequency of TTR Met 30 in familial amyloidotic polyneuropathy is not due to a founder effect. Hum. Mol. Genet. 1993, 2:1303.
44. Ikeda S., Nakazato M., Ando Y., Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan. Neurology 2002, 58:1001.
45. 55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum. Genet. 1992, 89:353.
46. Katsuragi S., Miyakawa T., Ando Y., Terazaki H. High-resolution ultrastructure of amyloid fibrils in familial amyloid polyneuropathy. J. Electron Microsc. (Tokyo) 2000, 49:579.
47. Kiuru S., Matikainen E., Kupari M., et al. Autonomic nervous system and cardiac involvement in familial amyloidosis, Finnish type (FAF). J. Neurol. Sci. 1994, 126:40.
48. Kiuru S., Salonen O., Haltia M. Gelsolin-related spinal and cerebral amyloid angiopathy. Ann. Neurol. 1999, 45:305.
49. Kiuru S., Seppalainen A.M. Neuropathy in familial amyloidosis, Finnish type (FAF): electrophysiological studies. Muscle Nerve 1994, 17:299.
50. Kiuru S., Seppalainen A.-M., Salonen S., et al. CNS abnormalities in patients with familial amyloidosis of the Finnish type (FAF). Amyloid Int. J. Exp. Clin. Invest. 1995, 2:22.
51. Klabunde T., Petrassi H.P., Oza V.B., et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 2000, 7:312.
52. Königstein H. Über Amyloidose der haut. Arch. Dermatol. Syphilis 1925, 148:330.
53. Kotani N., Hatori T., Yamagata S., et al. Transthyretin Thr60Ala Appalachian-type mutation in a Japanese family with familial amyloidotic polyneuropathy. Amyloid 2002, 9:31.
54. Kyle R.A. Amyloidosis. J. Intern. Med. 1992, 232:507.
55. Levy E., Haltia M., Fernandez-Madrid I., et al. Mutation in gelsolin gene in Finnish hereditary amyloidosis. J. Exp. Med. 1990, 172:1865.
56. Mahloudji M., Teasdall R.D., Adamkiewics J.J., et al. The genetic amyloidoses with particular reference to hereditary neuropathic amyloidosis, type II (Indiana or RGBRavina type). Medicine 1969, 48:1.
57. Maury C.P., Nurmiaho-Lassila E.L., Rossi H. Amyloid fibril formation in gelsolin derived amyloidosis: definition of the amyloidogenic region and evidence of accelerated amyloid formation of mutant Asn-187 and Tyr-187 gelsolin peptides. Lab. Invest. 1994, 70:558.
58. Mendell J.R. Familial amyloid polyneuropathies. Diagnosis and Management of Peripheral Nerve Disorders 2001, 477. Oxford University Press, New York. J.R. Mendell, J.T. Kissel, D.R. Cornblath (Eds.).
59. Meretoja J. Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. Ann. Clin. Res. 1969, 1:314.
60. Moses A.C., Rosen H.N., Moller D.E., et al. A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia. J. Clin. Invest. 1986, 86:2025.
61. Murakami T., Maeda S., Yi S., et al. A novel transthyretin mutation associated with familial amyloidotic polyneur-opathy. Biochem. Biophys. Res. Commun. 1992, 182:520.
62. Nichols W.C., Dwulet F.E., Liepnieks J., Benson M.D. Variant apolipoprotein A-1 as a major constituent of a human hereditary amyloid. Biochem. Biophys. Res. Commun. 1988, 156:762.
63. Nichols W.C., Gregg R.E., Brewer H., Benson M.D. A mutation in apolipoprotein A-1 in the Iowa type of familial amyloidotic polyneuropathy. Genomics 1990, 8:318.
64. Nichols W.C., Liepnieks J.J., McKusick V.A., Benson M.D. Direct sequencing of the gene for Maryland/German familial amyloidotic polyneuropathy type II and genotyping by allele-specific enzymatic amplification. Genomics 1989, 5:535.
65. Olofsson B.-E., Backman C., Karp K., Suhr O.B. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type 1. Transplantation 2002, 73:745.
66. Orita M., Iwahana H., Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:2766.
67. Pepys M.B., Herbert J., Hutchinson W.L., et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417:254.
68. Pitkanen P., Westermark P., Cornwell G.G. Senile systemic amyloidosis. Am. J. Pathol. 1984, 117:391.
69. Planté-Bordeneuve V., Lalu T., Misrahi M., et al. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology 1998, 51:708.
70. Planté-Bordeneuve V., Said G. Transthyretin related familial amyloidotic polyneuropathy. Curr. Opin. Neurol. 2000, 13:569.
71. Pomfret E.A., Lewis W.D., Jenkins R.L., et al. Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation 1998, 65:918.
72. Reilly M., Adams D., Davis M.B., et al. Haplotype analysis of French, British and other European patients with familial amyloid polyneuropathy. J. Neurol. 1995, 242:664.
73. Reilly M.M., Adams D., Booth D.R., et al. Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Brain 1995, 118:849.
74. Reilly M.M., King R.H.M. Familial amyloid polyneuropathy. Brain Pathol. 1993, 3:165.
75. Reilly M.M., Staunton H. Peripheral nerve amyloidosis. Brain Pathol. 1996, 6:163.
76. Reilly M.M., Staunton H., Harding A.E. Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic and epidemiology study. J. Neurol. Neurosurg. Psychiatry 1995, 59:45.
77. Rhyd A., Suhr O., Hietala S.-O., et al. Serum amyloid P scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur. J. Nucl. Med. 1998, 25:709.
78. Sacchettini J.C., Kelly J.W. Therapeutic strategies for human amyloid diseases. Nat. Rev. 2002, 1:267.
79. Sandgren O., Holmgren G., Lundgren E. Vitreous amyloidosis associated with homozygosity for the transthyretin methionine-30 gene. Arch. Ophthalmol. 1990, 108:1584.
80. Saraiva M.J.M. Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett. 2001, 498:201.
81. Saraiva M.J.M. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum. Mutat. 2001, 17:493.
82. Shaz B.H., Gordon F., Lewis W.D., et al. Orthotopic liver transplantation for familial amyloidotic polyneuropathy: a pathological study. Hum. Pathol. 2000, 31:40.
83. Soares M., Buxbaum J., Coehlo T., et al. Genetic anticipation in Portuguese kindreds with familial amyloidotic polyneuropathy is unlikely to be caused by triplet repeat expansions. Hum. Genet. 1999, 104:480.
84. Sousa A., Andersson R., Drugge U., et al. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum. Hered. 1993, 43:288.
85. Sousa A., Coehlo T., Barros J., Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type 1 in Povoa do Varzim and Vila do Conde (north of Portugal). Am. J. Hum. Genet. 1995, 60:512.
86. Sousa M.M., Cardoso I., Fernandes R., et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 2001, 159:1993.
87. Sousa M.M., Yan S.D., Fernandes R., et al. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J. Neurosci. 2001, 21:7576.
88. Stangou A.J., Hawkins P.N., Heaton N.D., et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy. Transplantation 1998, 66:229.
89. Staunton H., Dervan P., Linke R.P., Kelly P. Hereditary amyloid polyneuropathy in North West Ireland. Brain 1987, 110:1231.
90. Suhr O.B., Herlinius G., Friman S., Ericzon B.-G. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl. 2000, 6:263.
91. Sunada Y., Shimizu T., Nakase H., et al. Inherited amyloid polyneuropathy type IV (gelsolin variant) in a Japanese family. Ann. Neurol. 1993, 33:57.
92. Takaoka Y., Tashiro F., Yi S., et al. Comparison of amyloid deposition in two lines of transgenic mouse that model familial amyloidotic polyneuropathy, type 1. Transgenic Res. 1997, 6:261.
93. Tanaka K., Yamada T., Ohyagi Y., et al. Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. J. Neurol. Sci. 2001, 183:79.
94. Terzaki H., Ando Y., Misumi S., et al. A novel compound heterozygote (FAP ATTR Arg104His/Val30Met) with high serum transthyretin (TTR) and retinal binding protein (RBP) levels. Biochem. Biophys. Res. Commun. 1999, 264:365.
95. Thomas P.K., King R.H.M. Peripheral nerve changes in amyloid neuropathy. Brain 1974, 97:395.
96. Togashi S., Watanabe H., Nagasaka T., et al. An aggressive familial amyloidotic polyneuropathy caused by a new variant transthyretin Lys 54. Neurology 1999, 53:637.
97. Uemichi T., Liepnieks J.J., Benson M.D. A trinu-cleotide deletion in the transthyretin gene (delta V 122) in a kindred with familial amyloidotic polyneuropathy. Neurology 1997, 48:1667.
98. Van Allen M.W., Frohlich J.A., Davis J.R. Inherited predisposition to generalized amyloidosis: clinical and pathological study of a family with neuropathy, nephropathy and peptic ulcer. Neurology 1969, 19:10.
99. Virchow R. Découverte ďune substance qui donne lieu au měmes reactions chimiques que la cellulose vegetable, dans le corps human. C. R. Acad. Sci. (Paris) 1853, 37:492.
100. Wallace M.R., Dwulet F.E., Williams E.C., et al. Identification of a new hereditary amyloidosis prealbumin variant, Tyr 77, and detection of the gene by DNA analysis. J. Clin. Invest. 1988, 81:189.
101. Wallace M.R., Naylor S.L., Kluve-Beckerman B., et al. Localization of the pre-albumin gene to chromosome 18. Biochem. Biophys. Res. Commun. 1985, 129:753.
102. Westermark P., Sletten K., Johansson B., Cornwell G.G. Fibril in senile systemic amyloidosis derived from normal transthyretin. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:2843.
103. Yazaki M., Tokuda T., Nakamura A., et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem. Biophys. Res. Commun. 2000, 274:702.
104. Yazaki M., Yamashita T., Kincaid J.C., et al. Rapidly progressive amyloid polyneuropathy associated with a novel variant transthyretin serine 25. Muscle Nerve. 2002, 25:244.
105. Yin H.L., Kwaitkowski D.J., Mole J.E., et al. Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin. J. Biol. Chem. 1984, 259:5271.
106. Yoshioka K., Furuya H., Saraiva M.J.M., et al. Haplotype analysis of familial amyloidotic polyneuropathy. Hum. Genet. 1989, 82:9.